Cover Image: October 2009 Scientific American Magazine See Inside

Playing the Averages: The Risks of Pharmaceutical Advances

Acting Editor in Chief Mariette DiChristina introduces the October 2009 issue of Scientific American















Share on Tumblr



Better brains from a bottle? Image: Splashlight

“The year was 2081, and everybody was finally equal. They weren’t only equal before God and the law. They were equal every which way. Nobody was smarter than anybody else. Nobody was better looking than anybody else. Nobody was stronger or quicker than anybody else.”

In the opening of the classic 1961 short story “Harrison Bergeron,” novelist Kurt Vonnegut depicted a future in which people who had been born superior in some way over “average” people could not use those gifts to take “unfair” advantage. The strong lugged handicapping weights, the beautiful wore hideous masks and the clever were not permitted to think for stretches longer than 20 seconds or so. “A little mental handicap radio” transmitted earsplitting sounds such as a buzzer, a 21-gun salute or a ball-peen hammer striking a milk bottle. In response, “thoughts fled in panic, like bandits from a burglar alarm.”

Gun-toting government agents enforced the legislated baseline of mediocrity. When dull but well-meaning Hazel suggests that her husband, George, remove a few lead balls from his “handicap bag,” he reminds her of the fines and why he mustn’t disobey anyway: “‘If I tried to get away with it,’ said George, ‘then other people’d get away with it and pretty soon we’d be right back in the dark ages again, with everybody competing against everybody else. You wouldn’t like that, would you?’” No, she wouldn’t.

The must-have standards in the real 2081 will likely differ from Vonnegut’s unhappy tale, but the desire to achieve them may be uncomfortably similar. Our society, too, seems to be transfixed by the goal of reaching an average—one that is “above average.” With cosmetic surgery, we sculpt our bodies to create an ideal of attractiveness. Athletes dip into the medicine cabinet to pump up muscles and speed. Is it any wonder that recent headlines bark about the possibility of taking pills to boost brainpower?

As senior writer Gary Stix writes in the cover story, “Turbocharging the Brain,” older workers feel the need to vie with agile younger minds, students are pressed to make good grades while pulling all-nighters, and multitaskers want to maintain focus. Pills offer a tantalizingly easy solution. But would such drugs actually be an effective means of sharpening thought, and would they be as relatively harmless over the long term as having the occasional cup of coffee? Click here for an exploration of the science of enhancing cognition—and the issues that it raises.

While many people reach eagerly for bottled brain improvements, others are wary of medical enhancements—in the form of more potent vaccines—that would benefit overall public health. Nathalie Garçon and Michel Goldman describe new adjuvants, ingredients that help to stimulate the human immune system, in “Boosting Vaccine Power.” But hesitation by the public and policy leaders has slowed acceptance in the U.S., as we explain in Perspectives. Our unequal enthusiasms about what is important to improve say much about the choices we make.

Note: This article was originally printed with the title, "Playing the Averages."



This article was originally published with the title Playing the Averages.



Subscribe     Buy This Issue

Already a Digital subscriber? Sign-in Now
If your institution has site license access, enter here.

1 Comments

Add Comment
View
  1. 1. Human52 04:32 PM 9/23/09

    The real threat is not conformity, but the fact that the "new" drugs have worse side effects than the ailment they are taken for. and you are told about it! This hit and miss method employed by Big Pharm is reprehensible, and criminal.
    Oh, but the profits! And the growing population of ageing people who need care, and are too suceptable, is just too hard to pass up!

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

Playing the Averages: The Risks of Pharmaceutical Advances: Scientific American Magazine

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X